These three graphics show investors what they need to know about the genetic testing company.
There could be more problems in store for Illumina based on its disappointing sneak peek at Q3 revenue.
Shares drop in response to preliminary third-quarter results that came in well short of management's guidance.
The rumors of a $30 billion megamerger likely don’t hold water, but they could still point to some upside in gene-sequencing stocks.
Pacific Biosciences is growing more quickly than Illumina, which is struggling to overcome sluggish demand in Europe.
The cancer-test company continues to increase revenue, resulting in a smaller loss for the second quarter.
Optimism that its latest sequencing machine will catapult the company's sales higher is sparking a rally.
Growth in sequencing array and consumables sales enables this genomic-sequencing leader to post solid Q2 results.
Volume growth from the cancer-test maker was outstanding, and while there's work to go on reimbursement, revenue increased 19% year over year.
A pre-announcement of disappointing first-quarter financials weighed down shares in this gene-sequencing giant.